WallStSmart

Cytek Biosciences Inc (CTKB)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 17511% more annual revenue ($35.48B vs $201.49M). MDT leads profitability with a 13.0% profit margin vs -33.0%. MDT earns a higher WallStSmart Score of 56/100 (C).

CTKB

Hold

41

out of 100

Grade: D

Growth: 7.3Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 3.19

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CTKB.

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$86.58

$62.24 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTKB4 strengths · Avg: 9.5/10
EPS GrowthGrowth
73.5%10/10

Earnings expanding 73.5% YoY

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.1910/10

Safe zone — low bankruptcy risk

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

CTKB4 concerns · Avg: 2.5/10
Market CapQuality
$575.90M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-18.0%2/10

ROE of -18.0% — below average capital efficiency

Free Cash FlowQuality
$-1.77M2/10

Negative free cash flow — burning cash

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : CTKB

The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Altman Z-Score.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : CTKB

The primary concerns for CTKB are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

CTKB profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.

CTKB carries more volatility with a beta of 1.31 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cytek Biosciences Inc

HEALTHCARE · MEDICAL DEVICES · USA

Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, providing state-of-the-art cell analysis solutions to the life sciences industry. The company's advanced technologies facilitate comprehensive cellular analyses that are crucial for research in immunology, cancer diagnostics, and drug development. With a commitment to innovation and excellence in customer service, Cytek has solidified its status as a key contributor in the biotechnology sector, addressing the growing need for precise cell analysis tools. Boasting a diverse product portfolio and a robust market position, the company continues to drive advancements in the rapidly evolving field of cell biology research.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?